Nuvectis Pharma Inc.

Company Overview

Business Model: NUVECTIS PHARMA, INC. is a clinical-stage biopharmaceutical company focused on developing innovative precision medicines for serious conditions of unmet medical need in oncology. The Company's approach translates scientific insights into oncogenic drivers and pathway addiction into potent and highly selective anticancer drugs, targeting genetically defined patient populations. As of December 31, 2025, the Company has no products approved for commercial sale and has not generated any revenue from product sales.

Market Position: NUVECTIS PHARMA, INC. operates in the intensely competitive biopharmaceutical industry, specifically targeting the SRC/YES1 kinase space in oncology. The Company's lead product candidate, NXP900, is a targeted therapy that inhibits SRC and YES1 kinases. While multi-kinase inhibitors like Dasatinib (SPRYCEL®) and bosutinib (BOSULIF®) inhibit SRC/YES1 catalytic activity and are approved for hematological malignancies, they have shown only minor clinical activity in solid tumors. Saracatinib, another SRC/Abl inhibitor, was discontinued in Phase 2. NUVECTIS PHARMA, INC. highlights NXP900's novel mechanism of action, which induces and locks SRC in its native inactive conformation, inhibiting both catalytic and scaffolding functions, and its high selectivity. There are currently no FDA-approved selective YES1 inhibitors.

Recent Strategic Developments:

• NXP900 Clinical Progress: In July 2025, NUVECTIS PHARMA, INC. completed the Phase 1a part of its clinical trial for NXP900 in patients with advanced solid tumors. The study evaluated safety, tolerability, and pharmacokinetic properties, identifying a dose range of 20 to 300 mg/day without reaching dose-limiting toxicity. The most common adverse events were mild to moderate gastrointestinal-related issues. A robust pharmacodynamic response, demonstrating approximately 90% inhibition of SRC kinase phosphorylation, was observed at doses of 150 mg/day and higher, suggesting a potentially wide therapeutic window and supporting once-daily oral dosing. In August 2025, the Company initiated the Phase 1b expansion portion of the study, evaluating NXP900 as a single agent in specific tumor types and in combination with market-leading epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors. A clinical drug-drug interaction (DDI) study in healthy volunteers, completed in July 2025, classified NXP900 as a weak inhibitor of the cytochrome P450 enzyme CYP3A, with no serious or severe adverse events reported.
• NXP800 Development Cessation: In July 2025, following the completion of a Phase 1b clinical study, NUVECTIS PHARMA, INC. decided to cease clinical development of NXP800 and is assessing possible next steps.
• Capital Raising: In February 2025, the Company completed a public offering of 3,105,000 shares of common stock at $5.00 per share, generating net proceeds of approximately $13.9 million after deducting underwriting discounts and commissions and other offering expenses. Additionally, during the year ended December 31, 2025, the Company sold 1,996,028 shares of common stock under its At-the-Market (ATM) offering program, generating aggregate net proceeds of approximately $15.2 million.

Geographic Footprint: NUVECTIS PHARMA, INC.'s principal executive offices are located in Fort Lee, NJ. The Company has licensed NXP900 from the University of Edinburgh in Scotland and NXP800 from the CRT Pioneer Fund, which acquired it from the Institute of Cancer Research in London, UK. The Company holds worldwide commercial rights for NXP900 and conducts clinical trials in the U.S.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 0.0% (No revenue)
• Operating Margin: N/A (No revenue)
• Net Margin: N/A (No revenue)

Investment in Growth:

• R&D Expenditure: $18.2 million (2025) (N/A% of revenue)
• Capital Expenditures: $0 (2025)
• Strategic Investments:
  • License milestone fees: $2.4 million (2025)
  • Commitment to University of Edinburgh for future fund raisings: $1.8 million remaining (out of $3.0 million cumulative total) as of December 31, 2025.
  • Commitment to University of Edinburgh for R&D support: up to £580,000 (approximately $772,000) over 18 months (not yet begun as of December 31, 2025).

Business Segment Analysis

NUVECTIS PHARMA, INC. operates in one reportable segment, focusing on the development of precision medicines for oncology. Management evaluates the Company's performance based on unified internal reporting.

NXP900

Financial Performance:

• Revenue: $0 (clinical stage)
• Operating Margin: N/A (clinical stage)
• Key Growth Drivers: Advancement through Phase 1b clinical trials (single agent and combination with EGFR/ALK inhibitors), positive safety and efficacy data, and potential for broad application in various solid tumors where SRC and YES1 kinases are aberrantly activated. Product Portfolio:
• NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases.
• Its novel mechanism of action induces and locks SRC in its native inactive conformation, inhibiting both catalytic and scaffolding functions.
• Preclinical studies demonstrated inhibition of primary and metastatic tumor growth in xenograft models of breast, esophageal, head and neck cancers, and medulloblastoma.
• Publications suggest potential to reverse resistance to osimertinib (Tagrisso®) in non-small cell lung cancer and enzalutamide (Xtandi®) in metastatic, castration-resistant prostate cancer, in combination with these agents. Market Dynamics:
• SRC is aberrantly activated in many solid tumor cancers (e.g., breast, colon, prostate, pancreatic, ovarian), associated with late-stage cancers, metastatic potential, and therapy resistance.
• YES1 is amplified and overexpressed in many tumor types (e.g., squamous cell, mesothelioma, papillary kidney, lung, head and neck, bladder, esophageal), promoting cell proliferation, survival, and invasiveness.
• YES1 gene amplification is a mechanism of resistance to EGFR, ALK, and HER2 inhibitors.
• There are no FDA-approved selective YES1 inhibitors. Intellectual Property:
• Licensed worldwide commercial rights from the University of Edinburgh in August 2021.
• One patent family covers the composition of matter for NXP900, with patents granted in the U.S., European Union, China, and Japan, and a patent application pending in Canada.
• Statutory expiration for this patent family is April 2036, without considering any possible patent term extensions.

NXP800

Financial Performance:

• Revenue: $0 (clinical stage, development ceased)
• Operating Margin: N/A (clinical stage, development ceased)
• Key Growth Drivers: Clinical development ceased in July 2025. Product Portfolio:
• NXP800 was a small molecule product candidate. Market Dynamics:
• Clinical development was focused on platinum-resistant ARID1a-mutated ovarian carcinoma. Intellectual Property:
• Licensed worldwide exclusive rights from the CRT Pioneer Fund in May 2021.
• The key composition of matter patent for NXP800 expires in October 2034.
• Following the cessation of clinical development in July 2025, the Company is not planning any future manufacturing campaigns for NXP800.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: NUVECTIS PHARMA, INC. has never paid cash dividends on its capital stock and currently intends to retain future earnings, if any, for business development, operation, and expansion.
• Dividend Yield: N/A
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position (as of December 31, 2025):

• Cash and Equivalents: $31.6 million
• Total Debt: Not explicitly stated as long-term debt. Current liabilities total $13.3 million.
• Net Cash Position: $31.6 million (assuming no significant long-term debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable, as no significant long-term debt is disclosed.

Cash Flow Generation (Year ended December 31, 2025):

• Operating Cash Flow: $(16.0) million
• Free Cash Flow: $(16.0) million (assuming no capital expenditures)
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: NUVECTIS PHARMA, INC. does not own or lease manufacturing facilities. The Company relies on third-party manufacturers for the production of drug substance and drug product for clinical trials, adhering to current Good Manufacturing Practices (cGMPs). This includes a single, sole source manufacturer for NXP900 drug substance and another single, sole source manufacturer for NXP900 finished drug product.

Supply Chain Architecture: The Company's supply chain is structured around reliance on third-party manufacturers for raw materials, drug substance, and drug product for its clinical programs.

Key Suppliers & Partners:

• Manufacturing: The Company relies on a single, sole source manufacturer for NXP900 drug substance and another single, sole source manufacturer for NXP900 finished drug product.
• Clinical Research: The Company utilizes independent investigators, collaborators (such as medical institutions), Contract Research Organizations (CROs), and clinical trial sites to conduct and support its preclinical studies and clinical trials.
• Technology Partners: The Company has a license agreement with the University of Edinburgh for NXP900 and has agreed to provide funding for additional scientific research and preclinical testing for the NXP900 Program.

Facility Network:

• Manufacturing: NUVECTIS PHARMA, INC. does not own or lease any manufacturing facilities.
• Research & Development: Not explicitly detailed.
• Distribution: Not applicable at the current clinical stage.

Operational Metrics: Specific operational metrics such as capacity utilization or efficiency measures are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: NUVECTIS PHARMA, INC. currently has no marketing and sales organization and limited experience in marketing products. If any product candidates receive regulatory approval, the Company plans to either establish internal sales, marketing, and distribution capabilities or pursue arrangements with third-party collaborators.

Customer Portfolio: The Company's development efforts are focused on patients with specific molecular alterations in cancer, indicating a strategy targeting genetically defined patient populations.

Geographic Revenue Distribution: As NUVECTIS PHARMA, INC. has not generated any revenue from product sales, there is no geographic revenue distribution to report.

Competitive Intelligence

Market Structure & Dynamics

The biopharmaceutical industry is intensely competitive and characterized by rapid and significant technological changes. The use of precision medicines as a potential cancer treatment is a relatively recent development. NUVECTIS PHARMA, INC. faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions and research institutes.

Competitive Positioning Matrix:

Direct Competitors

• Dasatinib (SPRYCEL®): A multi-kinase inhibitor that potently inhibits the catalytic activity of SRC/YES1, as well as Abl and other kinases. Approved for Philadelphia chromosome-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia (hematological malignancies). Demonstrated only minor clinical activity in solid tumors.
• Bosutinib (BOSULIF®): Another multi-kinase inhibitor with similar activity to Dasatinib, approved for hematological malignancies. Also showed only minor clinical activity in solid tumors.
• Saracatinib: An inhibitor of SRC/Abl kinases, originally developed by AstraZeneca for various cancer types but discontinued in Phase 2.

Emerging Competitive Threats: The Company acknowledges the potential for competitors to obtain regulatory approval more rapidly, develop more effective or less costly drugs, or secure intellectual property rights that limit NUVECTIS PHARMA, INC.'s ability to commercialize its candidates.

Competitive Response Strategy: NUVECTIS PHARMA, INC. aims to leverage its scientific knowledge, technology, and development expertise to build a global biopharmaceutical company. Its strategy includes developing NXP900 as a potential differentiated therapy, maximizing its therapeutic potential, and evaluating opportunities to accelerate development.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The Company's product candidates target specific molecular alterations, potentially limiting patient populations. Successful identification of patients may depend on developing companion diagnostics. There is no certainty that target patient populations will be large enough for profitability.
• Technology Disruption: The industry is intensely competitive and subject to rapid technological changes. Competitors may develop more effective, convenient, or less costly drugs, or obtain regulatory approvals more rapidly.
• Customer Concentration: Not applicable at the current clinical stage.

Operational & Execution Risks

• Supply Chain Vulnerabilities: NUVECTIS PHARMA, INC. relies on single, sole source third-party manufacturers for NXP900 drug substance and finished drug product. This reliance increases the risk of insufficient quantities, quality issues, or delays, which could impair development or commercialization efforts.
• Geographic Concentration: Not explicitly detailed as a specific risk.
• Capacity Constraints: Risk that third-party manufacturers may be unable to meet future demand.

Financial & Regulatory Risks

• Market & Financial Risks: NUVECTIS PHARMA, INC. has a limited operating history, has incurred significant losses since inception (accumulated deficit of $99.7 million as of December 31, 2025), and has not generated product revenue. The Company will require substantial additional funding, which may lead to dilution for existing stockholders or require relinquishing proprietary rights.
• Regulatory & Compliance Risks: The drug development and approval process is lengthy, expensive, and uncertain. Denial or delay of regulatory approvals (FDA, EMA, etc.) could prevent or delay commercialization. Post-approval, the Company will be subject to extensive ongoing regulatory obligations (e.g., cGMP, safety reporting). Changes in healthcare laws and policies, including drug pricing reforms (e.g., Inflation Reduction Act, MFN pricing schemes), could adversely affect profitability and market acceptance. Non-compliance with anti-kickback, fraud and abuse, false claims, and privacy laws could result in significant penalties.

Geopolitical & External Risks

• Geopolitical Exposure: Uncertainty and changes in U.S. trade policies, including tariffs and trade restrictions, could adversely affect input costs, supply chain, and demand for products.
• Trade Relations: Rising trade and political tensions could disrupt supply chains, limit availability of goods, and affect the ability to sell products in certain countries.
• Sanctions & Export Controls: Not explicitly detailed as a specific risk.
• Major Public Health Issues: Health epidemics (e.g., COVID-19) could cause delays in clinical trials, divert healthcare resources, interrupt supply chains, and disrupt regulatory approval processes.

Innovation & Technology Leadership

Research & Development Focus:

• Core Technology Areas: NUVECTIS PHARMA, INC. focuses on precision medicines for oncology, specifically small molecule therapeutics that target oncogenic drivers and pathway addiction. A key area is the inhibition of SRC and YES1 kinases.
• Innovation Pipeline: The lead candidate, NXP900, is in Phase 1b clinical development. The Company plans to conduct additional in vivo studies to further understand the effects of YES1 inhibition in solid tumors driven by YES1 overexpression or gene amplification.

Intellectual Property Portfolio:

• Patent Strategy: The Company strives to protect its proprietary technologies through patents, patent applications, trade secrets, and license agreements. For NXP900, it has licensed one patent family covering the composition of matter, with patents granted in the U.S., EU, Japan, and China, and a patent application pending in Canada. The statutory expiration for this patent family is April 2036, without considering any possible patent term extensions.
• Licensing Programs: NUVECTIS PHARMA, INC. holds a worldwide, exclusive license agreement with the University of Edinburgh for NXP900 and its derivatives. It also previously held a worldwide, exclusive license agreement with the CRT Pioneer Fund for NXP800, which has ceased clinical development.
• IP Litigation: No material IP litigation is disclosed.

Technology Partnerships: NUVECTIS PHARMA, INC. collaborates with the University of Edinburgh, providing research and development support to generate preclinical data for NXP900, support IND submissions, and inform patient selection strategies.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The executive officers have been with the Company since its inception or early stages. The Company's future success depends on its ability to attract and retain highly qualified managerial, scientific, and medical personnel.

Board Composition: The Board of Directors consists of five members: Ron Bentsur (Chairman, CEO, and President), Kenneth Hoberman, Matthew Kaplan, James F. Oliviero, and Juan Sanchez. Four of the five directors are independent. Ron Bentsur serves as both CEO and Chairman. The Board administers risk oversight directly and through its Audit and Compensation committees.

Human Capital Strategy

Workforce Composition:

• Total Employees: 13 full-time employees (as of February 6, 2026).
• Geographic Distribution: Not explicitly detailed.
• Skill Mix: The Company relies on managerial, scientific, and medical personnel, supplemented by expert consultants and vendors.

Talent Management:

• Acquisition & Retention: NUVECTIS PHARMA, INC. utilizes an equity incentive plan to attract, retain, and motivate selected employees, consultants, and directors through stock-based compensation awards and cash-based bonus awards.
• Retention Metrics: Not explicitly disclosed.
• Employee Value Proposition: Not explicitly detailed beyond compensation.

Diversity & Development: Not explicitly detailed in the filing. Culture & Engagement: Not explicitly detailed in the filing.

Environmental & Social Impact

Environmental Commitments: NUVECTIS PHARMA, INC. is subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. The Company relies on third parties for disposal of these materials. No specific environmental commitments, emissions targets, or carbon neutrality goals are disclosed.

Supply Chain Sustainability: Not explicitly detailed in the filing.

Social Impact Initiatives: Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns: Not applicable at the current clinical development stage, as the Company has no commercial products. Economic Sensitivity: The Company's business is affected by global and local economic and political conditions, including financial markets, inflation, recession, and policy initiatives. Industry Cycles: Not explicitly detailed beyond general industry competition.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: NUVECTIS PHARMA, INC. is subject to extensive regulation by numerous governmental authorities, primarily the U.S. Food and Drug Administration (FDA), as well as other state and foreign regulatory agencies. These regulations cover clinical development, manufacturing, commercialization, marketing, and sale of product candidates. Compliance with current Good Manufacturing Practices (cGMPs), Good Clinical Practices (GCPs), and Good Laboratory Practices (GLPs) is required.

Industry-Specific Regulations: The Company must comply with the Federal Food, Drug and Cosmetic Act and similar foreign regulations. The regulatory approval process is lengthy, complex, and expensive. Post-approval, activities such as manufacturing, labeling, advertising, and record-keeping are subject to ongoing regulatory requirements.

• International Compliance: Obtaining regulatory approval in one jurisdiction does not guarantee approval in others. Foreign regulatory authorities have varying requirements, which can involve additional studies and administrative review periods.

Trade & Export Controls: Not explicitly detailed beyond general risk factors.

Legal Proceedings: As of the date of the report, NUVECTIS PHARMA, INC. was not a party to any material legal matters or claims.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's effective tax rate is below the U.S. federal statutory income tax rate of 21% primarily due to state income taxes (net of federal benefit) and the establishment of a full valuation allowance on its deferred tax assets.
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), enacted on July 4, 2025, maintained the 21% corporate tax rate and made permanent beneficial tax provisions from the Tax Cuts and Jobs Act of 2017, including immediate expensing of domestic research and development expenditures, more favorable interest deductibility, and 100% bonus depreciation, effective in 2025. Revisions to the international tax framework are effective in 2026.

Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the Company had accumulated tax loss carryforwards of approximately $56.1 million. Under U.S. tax laws, these carryforwards have no expiration date but are limited to 80% of the Company's taxable income in any given tax year. A full valuation allowance has been recorded against the net deferred tax assets due to the Company's lack of earnings history and uncertainties regarding future taxable income.

Insurance & Risk Transfer

Risk Management Framework: NUVECTIS PHARMA, INC. maintains workers’ compensation insurance to cover employee injuries. The Company also has clinical trial insurance. Insurance Coverage: The Company does not maintain insurance for environmental liability or toxic tort claims. Risk Transfer Mechanisms: Not explicitly detailed beyond general insurance.